The White House is currently reviewing a federal plan for marijuana and CBD research.
The White House’s Office of Management and Budget (OMB) is reviewing a draft cannabis guidance document from FDA — possibly signaling progress in the public health agency’s examination of whether and how to regulate the market for CBD in dietary supplements and other products.
The document titled, Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research, was received by the OMB May 28th, 2020 — one year after FDA held an extensively publicized meeting about products containing cannabis.
FDA Makes Statement on CBD Research
“We recognize that there is a substantial public interest in marketing and accessing CBD for a variety of products. We are working toward a goal of providing additional guidance, and have made substantial progress,” an FDA representative stated. “There are many questions to explore regarding the science, safety, effectiveness, and quality of products containing CBD, and we need to do our due diligence.”
“As part of our work, the FDA continues to explore potential pathways for various types of CBD products to be lawfully marketed. An important component of this work is obtaining and evaluating information to address outstanding questions related to the safety of CBD products that will inform our consideration of potential regulatory frameworks for CBD while maintaining the FDA’s rigorous public health standards.”
Currently, the FDA is seeking public input about the safety and efficacy of CBD. The agency said in an update to Congress in March that it has several questions it wants to be answered before deciding whether the cannabidiol can be lawfully marketed. That includes questions about the impact of different methods of consumption and drug interactions.
While the OMB reviews the CBD products, hemp advocates in Washington, D.C. continue applying pressure on lawmakers on legislative solutions that would open up doors for CBD to be lawfully marketed in supplements and perhaps conventional food as well. ‘
Jonathan Miller, general counsel of the U.S. Hemp Roundtable, a coalition of companies and organizations in the hemp industry, is among those meeting with members of Congress and their staff at a time when the hemp industry, especially farmers, have struggled with financial woes, including a spate of bankruptcies.
“We’re really trying to work with our friends in Congress to force the FDA to act because that really is the lynchpin behind any recovery,” Miller said in a recent interview. “We are cognizant that the FDA has its hands full with COVID right now, but even before COVID struck, the FDA was moving in real baby steps, and we’ve got to get them to act.”